Suppression of hypoxia-induced HIF-1α accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 17-26

  Ban, Hyun Seung ^a   Uno, Masaharu ^a   Nakamura, Hiroyuki ^a  

^a GAKUSHUIN UNIVERSITY   (Japan)

Author keywords

AAL993; Hypoxia inducible factor; KRN633; SU5416; Vascular endothelial growth factor inhibitor

Indexed keywords

AAL 993; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRN 633; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA PRIMERS; DNA-DIRECTED DNA POLYMERASE; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; INDOLES; PHENYLUREA COMPOUNDS; PYRROLES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954761483     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.010     Document Type: Article

References (46)

1. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., Klausner R.D., Pause A. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 1999, 96:12436-12441.
2. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
3. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell. Biol. 2000, 2:423-427.
4. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 2001, 98:9630-9635.
5. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 2000, 275:25733-25741.
6. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274:6519-6525.
7. Berra E., Richard D.E., Gothie E., Pouyssegur J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 2001, 491:85-90.
8. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
9. 2 sensing. Science 2001, 292:464-468.
10. 2-regulated gene expression. FASEB J. 2002, 16:1151-1162.
11. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
12. Zelzer E., Levy Y., Kahana C., Shilo B.Z., Rubinstein M., Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J. 1998, 17:5085-5094.
13. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
14. Richard D.E., Berra E., Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J. Biol. Chem. 2000, 275:26765-26771.
15. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., Ferrara N., Johnson R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
16. Semenza G.L. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J. Clin. Invest. 2001, 108:39-40.
17. Feng C.W., Wang L.D., Jiao L.H., Liu B., Zheng S., Xie X.J. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2002, 2:8.
18. Long L., Rubin R., Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp. Cell. Res. 1998, 238:116-121.
19. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 1998, 95:14389-14394.
20. Kaipainen A., Korhonen J., Pajusola K., Aprelikova O., Persico M.G., Terman B.I., Alitalo K. The related FLT 4, FLT 1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J. Exp. Med. 1993, 178:2077-2088.
21. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 2006, 39:469-478.
22. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp. Cell. Res. 1999, 253:117-130.
23. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
24. Los M., Roodhart J.M., Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12:443-450.
25. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7:3129-3140.
26. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., Ryan A.J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert. Opin. Investig. Drugs 2007, 16:239-249.
27. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., Wood J., Haberey M., Huth A., Kruger M., Menrad A., Ottow E., Seidelmann D., Siemeister G., Thierauch K.H. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem. 2002, 45:5687-5693.
28. Nakamura H., Sasaki Y., Uno M., Yoshikawa T., Asano T., Ban H.S., Fukazawa H., Shibuya M., Uehara Y. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. Bioorg. Med. Chem. Lett. 2006, 16:5127-5131.
29. Honda T., Tajima H., Kaneko Y., Ban M., Inaba T., Takeno Y., Okamoto K., Aono H. Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. Bioorg. Med. Chem. Lett. 2008, 18:2939-2943.
30. Wickens P., Kluender H., Dixon J., Brennan C., Achebe F., Bacchiocchi A., Bankston D., Bierer D., Brands M., Braun D., Brown M.S., Chuang C.Y., Dumas J., Enyedy I., Hofilena G., Hong Z., Housley T., Jones B., Khire U., Kreiman C., Kumarasinghe E., Lowinger T., Ott-Morgan R., Perkins L., Phillips B., Schoenleber R., Scott W.J., Sheeler R., Redman A., Sun X., Taylor I., Wang L., Wilhelm S., Zhang X., Zhang M., Sullivan E., Carter C., Miglarese M., Levy J. SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. Bioorg. Med. Chem. Lett. 2007, 17:4378-4381.
31. Lee K., Lee J.H., Boovanahalli S.K., Jin Y., Lee M., Jin X., Kim J.H., Hong Y.S., Lee J.J. (Aryloxyacetylamino) benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J. Med. Chem. 2007, 50:1675-1684.
32. Banerjee D., Liefshitz A. Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res. 2001, 21:3941-3947.
33. Obrig T.G., Culp W.J., McKeehan W.L., Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem. 1971, 246:174-181.
34. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64:993-998.
35. Janmaat M.L., Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 2003, 39(Suppl. C):61-80.
36. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12:363-369.
37. Westra J., Brouwer E., Bos R., Posthumus M.D., Doornbos-van der Meer B., Kallenberg C.G., Limburg P.C. Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann. NY. Acad. Sci. 2007, 1108:340-348.
38. Qian D., Lin H.Y., Wang H.M., Zhang X., Liu D.L., Li Q.L., Zhu C. Involvement of ERK1/2 pathway in TGF-beta1-induced VEGF secretion in normal human cytotrophoblast cells. Mol. Reproduct. Dev. 2004, 68:198-204.
39. Deudero J.J., Caramelo C., Castellanos M.C., Neria F., Fernandez-Sanchez R., Calabia O., Penate S., Gonzalez-Pacheco F.R. Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J. Biol. Chem. 2008, 283:11435-11444.
40. Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., Di Fiore P.P., Polo S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 2005, 102:2760-2765.
41. Row P.E., Clague M.J., Urbe S. Growth factors induce differential phosphorylation profiles of the Hrs-STAM complex: a common node in signalling networks with signal-specific properties. Biochem. J. 2005, 389:629-636.
42. He J., deCastro C.M., Vandenbark G.R., Busciglio J., Gabuzda D. Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. Proc. Natl. Acad. Sci. USA 1997, 94:3954-3959.
43. Follows G.A., Tagoh H., Lefevre P., Hodge D., Morgan G.J., Bonifer C. Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J. 2003, 22:2798-2809.
44. Pore N., Jiang Z., Gupta A., Cerniglia G., Kao G.D., Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006, 66:3197-3204.
45. Zhong X.S., Zheng J.Z., Reed E., Jiang B.H. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem. Biophys. Res. Commun. 2004, 324:471-480.
46. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.